ClinicalTrials.gg
CompletedNCT05489120Updated Aug 17, 2026

Low-Protein Diet With Low-Protein Foods Versus a LPD Without LP Foods in Patients With Chronic Kidney Disease (CKD)

An interventional study of Consumption of FLAVIS in Chronic Kidney Disease Stage 3B, Chronic Kidney Disease stage4 and Chronic Kidney Disease Stage 5, sponsored by Dr. Schär AG / SPA. Completed at 18 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Dr. Schär AG / SPA · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 238 studies in Renal Insufficiency, Chronic with a site in France — 55 open to participants now, 69 under way, 17 of them phase 3. Renal Insufficiency, Chronic · France.

Enrollment
77th of 165
210 · median 170
Started
2022
with 21 others
No phase
63 of 238
24 open now
Registered
176th of 238
by date

Among the 238 studies in Renal Insufficiency, Chronic with a site in France, this one is the 77th largest by enrollment of the 165 interventional ones that give a count, is one of 22 that started in 2022, is one of 63 with no phase, and was the 176th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

55 of the 238 studies in Renal Insufficiency, Chronic with a site in France are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 238 studies in Renal Insufficiency, Chronic with a site in France, or all of them as a file.
02

Study summary

The KDOQI 2020 - Clinical practice guideline for nutrition in chronic kidney disease (CKD) -recommends protein restriction to reduce the risk of end-stage renal disease/death and improve quality of life, a low protein diet providing 0.55-0.60g dietary protein/ kg body weight/day is recommended. FLAVIS® is a product line of hypoprotein foods specially developed for the treatment of CKD.The use of low-protein foods may facilitate the achievement of nutritional goals in terms of protein intake and help patients to follow a low-protein diet.

03

Conditions studied

  • Chronic Kidney Disease Stage 3B
  • Chronic Kidney Disease stage4
  • Chronic Kidney Disease Stage 5
  • Chronic Kidney Disease Stage 3A

Keywords

  • low-protein diet
  • low-protein foods
  • FLAVIS
  • compliance
  • effectiveness
  • safety
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • CKD patient stage 3a-5 (\<60 ml/min/1.73 m² estimated by formula) and not on dialysis,
  • With a good nutritional status (i.e., absence of malnutrition according to albumin, pre-albumine, and no clinical and paraclinical criteria of malnutrition),
  • Above 1g protein/ kg bw (ideal body weight),
  • LPD-naïve patient,
  • Motivated to LPD introduction (ensure during screening phase patient willingness to modify diet habits with counselling accurate follow-up),
  • Available to attend the visits planned by the protocol and able to complete the data collection documents (diet record and self-administered questionnaires),
  • Subject affiliated to a health insurance system or is a beneficiary (art. L.1121-11, Code of Public Health, France),
  • Having given their informed written consent regarding its participation to the protocol.

Exclusion criteria

Exclusion Criteria:

  • Patient for whom dialysis or transplantation is planned/expected within the next 12 months
  • Known allergic reactions to the ingredients present in FLAVIS products (milk, eggs, soy, nut),
  • Uncontrolled Diabetes ( >8.5%),
  • Active cancer (including a 5 years remission period),
  • Psychiatric disorders or inability to follow the protocol,
  • Evidence of any active infectious or uncontrolled inflammatory diseases,
  • Inability to provide blood samples (poor venous capital),
  • Inability to perform correct 24-hours urine collection,
  • Any change of the chronic medication within 1 month before screening,
  • Presence of any significant medical finding or significant history such as uncontrolled systemic diseases that may impact the safety, the interpretation of the results and/or the participation of the subject in the study according to the opinion of the investigator,
  • Patient with an active implanted medical device
  • Simultaneous participation in another clinical trial or subject still within the exclusion period of a previous clinical trial.
  • Vulnerable subjects (art. L. 1121-5 à 8 et L. 1122-1-2, Code of Public Health, France) are also excluded from the clinical trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (actual)

Study arms

  • No intervention
    COMPARATOR

    Follow-up of the CKD patient according to current practice i.e. low protein diet.

  • Experimental
    FLAVIS

    Follow-up of the CKD patient according to the current practice i.e. low protein diet with the addition of of low-protein products (FLAVIS).

    Other: Consumption of FLAVIS

Interventions

  • OtherConsumption of FLAVIS

    Patients of the FLAVIS group will recevied FLAVIS products in addition to their diet follow-up.

06

What researchers measure

Primary outcomes

  1. Effectiveness in terms of protein intake of a LPD with LP foods (FLAVIS products) compared to standard products (LPD without consumption of LP foods)

    Maroni formula : (Measurement of urea in urine + (\[patient weight\]\*0.031))\*6.25

    Time frame: 12 month

Secondary outcomes

  1. Protein intake during the 12 months follow-up

    Maroni formula: (Measurement of urea in urine + (\[patient weight\]\*0.031))\*6.25

    Time frame: 1 month, 3 month, 6 month and 9 month

  2. Dietary adherence

    3-day dietary record correlated to a 24-hour urine collection

    Time frame: baseline, 1 month, 3 month, 6 month and 12 month

  3. Dietary compliance for products under study

    quantities consumed of FLAVIS products.

    Time frame: monthly up to 12 months

  4. Effects of the LPD on BMI

    Weight and height will be combined to report BMI in kg/m\^2.

    Time frame: baseline, 1 month, 3 month, 6 month and 12 month

  5. Effects of the LPD on weight

    Weight in kg

    Time frame: baseline, 1 month, 3 month, 6 month and 12 month

  6. Effects of the LPD on body composition: water

    Water in litres

    Time frame: baseline, 1 month, 3 month, 6 month and 12 month

  7. Effects of the LPD on body composition: muscles

    Muscles in Kg

    Time frame: baseline, 1 month, 3 month, 6 month and 12 month

  8. Effects of the LPD on body composition: body protein content

    Body protein content in Kg

    Time frame: baseline, 1 month, 3 month, 6 month and 12 month

  9. Effects of the LPD on Blood

    Blood Chemistry

    Time frame: baseline, 1 month, 3 month, 6 month, 9 month and 12 month

  10. Effects of the LPD on Urine

    Urine Chemistry

    Time frame: baseline, 1 month, 3 month, 6 month, 9 month and 12 month

  11. Effects of the LPD on diabetic patient glycemic profile

    Hb1Ac will be measured

    Time frame: Baseline, 6 month and 12 month

  12. Incidence of Adverse Events [Safety of the LPD]

    Questioning and a clinical examination, biological analyses review

    Time frame: 1 month, 3 month, 6 month, 9 month and 12 month

  13. Incidence of Adverse Events [Safety of the LPD]

    4-points Likert scale

    Time frame: 3 month, 6 month and 12 month

  14. Patient quality of life

    SF-36 questionnaire score which from 0 to 100

    Time frame: baseline, 3 month, 6 month and 12 month

  15. Patient satisfaction with LPD

    Auto-questionnaire with numerical scales, closed-ended questions and Likert scales

    Time frame: 3 month, 6 month and 12 month

07

Study locations

18 sites
  • Clinique sainte isabelle
    Abbeville, 80100, France
  • Cabinet médical du Dr Magnant
    Aix-en-Provence, France
  • CHU Besançon
    Besançon, France
  • Maison du Rein
    Bordeaux, France
  • Polyclinique Bordeaux Nord Aquitaine
    Bordeaux, France
  • CH Chalon
    Chalon-sur-Saône, France
  • CHU Gabriel Montpied
    Clermont-Ferrand, France
  • CH Le Mans
    Le Mans, France
  • Hospices Civiles de Lyon
    Lyon, France
  • Saint Joseph Saint Luc
    Lyon, France
  • Hôpital la conception
    Marseille, France
  • CH Mâcon
    Mâcon, France
  • APHP - Hôpital Necker
    Paris, France
  • Tenon hospital -APHP
    Paris, France
  • Hôpital Drôme Nord
    Romans-sur-Isère, France
  • Nouvel Hôpital Civil
    Strasbourg, France
  • Calydial
    Vienne, France
  • Hôpital Nord-Ouest
    Villefranche-sur-Saône, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Jul 2026, 44 months.

Of 40 industry-sponsored interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 44 months is above that.

Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2022
First posted
Aug 5, 2022
StartActual
Nov 6, 2022
Primary completionActual
Jul 24, 2026
CompletionActual
Jul 24, 2026
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05489120
Lead sponsor
Dr. Schär AG / SPA
Collaborators
Slb Pharma
Responsible party
Sponsor
First posted
Aug 5, 2022
Start date
Nov 6, 2022
Primary completion
Jul 24, 2026
Completion
Jul 24, 2026
Last update
Aug 17, 2026

Study contacts

Laetitia Koppe, Dr
study director · HCL

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion